MarketPulse

relacorilant

31 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Corcept Therapeutics Hit with Class Action Over FDA Drug Study Misrepresentations

Law firm files securities lawsuit against $CORT alleging false statements about FDA interactions regarding relacorilant drug approval prospects.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Corcept Therapeutics

Rosen Law Firm sues Corcept Therapeutics for allegedly making misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug candidate.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Corcept Faces Securities Lawsuit Over Relacorilant Claims as FDA Rejection Triggers 50% Stock Decline

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Alleges Corcept Misrepresented Relacorilant Clinical Data

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Portnoy Law Firm Files Class Action Against Corcept Therapeutics Over FDA Drug Rejection

Portnoy Law Firm sues Corcept Therapeutics over alleged misrepresentations about drug candidate relacorilant, following FDA rejection that caused stock to plummet 50%.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Corcept Investors Face April Deadline in Securities Litigation Over FDA Rejection

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Corcept Faces Securities Lawsuit Over Relacorilant FDA Rejection

Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Therapeutics Faces Securities Fraud Lawsuit Over Undisclosed FDA Setback

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.
CORTBRBRQUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Corcept Therapeutics Faces Class Action Over Relacorilant Clinical Evidence Claims

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.
CORTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Law Firm Initiates Class Action Against Corcept Therapeutics Over Relacorilant Claims

Law firm Bernstein Liebhard files class action lawsuit against Corcept Therapeutics for alleged material misrepresentations about relacorilant drug clinical evidence.
SMRCORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

Corcept Therapeutics Faces Class Action Over Relacorilant FDA Rejection

Corcept Therapeutics faces class action lawsuit over alleged misrepresentation regarding relacorilant drug. FDA rejected the application citing insufficient efficacy data; stock plummeted over 50%.
CORTsecurities fraudclass action lawsuit